⌕
Sionna Therapeutics · SION · Nasdaq
Tenet 70 · Solid
Compare
$3.12−6.31%At closeTenet 70 · Solid
$3.12−0.21 (−6.31%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Sionna Therapeutics (SION) Stock

Sionna Therapeutics (SION) closed at $3.12 on Nov 16, 2026; its Tenet Score is 70 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$3.12
Nov 16, 2026
Market cap
$141.1M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
3.19 – 54.97
low → high
Tenet Score
70/100
Solid · 409 Healthcare peers

Industry: Pharmaceutical Preparations · see every company filed here →

Sionna Therapeutics Inc. scores 70/100. Solid. Strongest on value and financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 70 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
70/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
98
Quality
25
Health
88
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueA+QualityFHealthBGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
0.6×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
—
no P/S on file
ROE
−39%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
13.92
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 3y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Sionna Therapeutics Inc.

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance reg…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 37 US ETFs · top wrappers by weightSee all ETFs holding SION →

Similar-sized companies in Pharmaceutical Preparations

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Sionna Therapeutics in?

Sionna Therapeutics is in the Healthcare sector and the Pharmaceutical Preparations industry.

What is Sionna Therapeutics' Tenet Score?

Sionna Therapeutics' Tenet Score is 70 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.